WorksheetsAugust 2017_All topics
Total questions: 15
Worksheet time: 15mins
Name
Class
Date
1.
In LUME Lung 1 trial, median PFS was significantly better with nintedanib+docetaxel group in both adenocarcinoma and squamous cell carcinoma subgroups.
a)
True
b)
False
2.
Which of the following is true about nintedanib?
a)
The standard dose in NSCLC is 150 mg BD
b)
It is indicated in 2nd line therapy for Adenocarcinoma and Squamous cell carcinoma of lung
c)
It should be taken with food
d)
When combined with docetaxel, it worsens neutropenia
3.
Your doctor informs you that his patient on Afatinib 40 mg has grade 2 diarrhoea for last 4 days despite optimal care. What is the recommendation?
a)
Grade 2 diarrhoea is alright, the doctor can continue using Afatinib
b)
interrupt therapy till it subsides to ≤grade 1 or baseline
c)
interrupt treatment till recovery to ≤grade 1 or baseline and restart afatinib at 30 mg
d)
Stop Afatinib treatment permanently
4.
India participated in
a)
LUX Lung 8
b)
INPULSIS 1
c)
INPULSIS 2
d)
All of the above
5.
Which is false about LUX Lung 3 and 6?
a)
Afatinib 40 mg vs standard chemotherapy in 1:1 randomisation
b)
Afatinib showed more than 12 months OS benefit in del19 patients
c)
Afatinib had a better ORR with most patients responding by week 6
d)
Only patients with asymptomatic brain metastasis were included
6.
Which 2nd generation TKI showed significantly better PFS in EGFR+ NSCLC when compared to gefitinib in ARCHER 1050 trial? (Data presented at recently concluded ASCO)
a)
Nazartinib
b)
Alectinib
c)
Dacomitinib
d)
Osimertinib
7.
What is false about LUX Lung 7 trial?
a)
Afatinib 40 mg/day vs gefitinib 250 mg/day in EGFR+ adenocarcinoma in 1st line
b)
median PFS was 11 months vs 10.9 months which means there was no difference
c)
PFS, TTF and OS were co-primary endpoints
d)
Afatinib had a significantly better TTF and ORR
8.
Identify the false match
a)
LUX Lung 8 - Afatinib vs gefitinib
b)
LUX Lung 3 - Afatinib vs Cis/Pem
c)
LUX Lung 6 - Afatinib vs Cis/Gem
d)
LUX Lung 7 - Afatinib vs gefitinib
9.
In LUX Lung 8 trial Afatinib showed a significant reduction in relative risk of disease progression or death which was 19%.
a)
True
b)
False
10.
In which of the following situations, Nintedanib dose modification is necessary?
a)
mild to moderate renal impairment
b)
mild hepatic impairment
c)
grade 2 diarrhoea for more than 7 days despite anti-diarrhoeal treatment
d)
none of the above
11.
Eligibility criteria for INPUSIS trials included
a)
Definite UIP patients who showed honeycombing
b)
Possible UIP cases who did not show honeycombing on HRCT
c)
Patients of IPF with concomitant radiological emphysema
d)
All of the above
12.
In pooled analysis of INPULSIS trials, Nintedanib reduced the risk of time to adjudicated confirmed or suspected acute exacerbation by 68%
a)
True
b)
False
13.
Identify the set of trials where all the trials were positive.
a)
CAPACITY - 1, CAPACITY - 2, ASCEND
b)
TOMORROW, INPULSIS - 1, INPULSIS - 2
c)
Both
d)
None
14.
What is true with respect to Quality of Life (QoL) in LUME Lung 1 trial?
a)
Addition of Nintedanib to docetaxel resulted in worse QoL
b)
Addition of Nintedanib to docetaxel did not further deteriorate QoL
c)
addition of nintedanib to docetaxel improved QoL
d)
none of the above
15.
In LUME Lung 1, even though the incidence of diarrhoea was 43.4% with Nintedanib+docetaxel in adenocarcinoma patients, permanent discontinuation was <1%.
a)
True
b)
False
100 %
